Excess out‐of‐hospital deaths during the <scp>COVID</scp>‐19 outbreak: evidence of pulmonary embolism as a main determinant

Benzakoun, Joseph; Hmeydia, Ghazi; Delabarde, Tania; Hamza, Lilia; Méder, J.F.; Ludes, Bertrand; Mebazaa, Alexandre

doi:10.1002/ejhf.1916

Cited by 32 publications

(34 citation statements)

References 8 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The literature search yielded 425 studies, of which 295 remained after duplicates were removed and therefore were screened. Fifty (50) studies were reviewed in full text and 42 studies [ [4] , [5] , [6] , [7] , 9 , 10 , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] ] enrolling 8271 patients were eventually included in the meta-analysis. No studies were excluded from the meta-analysis on the basis of the language in which they were originally published.…”

Section: Resultsmentioning

confidence: 99%

Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis

Malas¹,

Naazie²,

et al. 2020

View full text Add to dashboard Cite

Background: Studies have suggested that there is increased risk of thromboembolism (TE) associated with coronavirus disease 2019 (COVID-19). However, overall arterial and venous TE rates of COVID-19 and effect of TE on COVID-19 mortality is unknown. Methods: We did a systematic review and meta-analysis of studies evaluating TE in COVID-19. We searched PubMed, Cochrane, and Embase for studies published up to June 12, 2020. Random effects models were used to produce summary TE rates and odds ratios (OR) of mortality in COVID-19 patients with TE compared to those without TE. Heterogeneity was quantified with I 2. Findings: Of 425 studies identified, 42 studies enrolling 8271 patients were included in the meta-analysis. Overall venous TE rate was 21% (95% CI:17À26%): ICU, 31% (95% CI: 23À39%). Overall deep vein thrombosis rate was 20% (95% CI: 13À28%): ICU, 28% (95% CI: 16À41%); postmortem, 35% (95% CI:15À57%). Overall pulmonary embolism rate was 13% (95% CI: 11À16%): ICU, 19% (95% CI:14À25%); postmortem, 22% (95% CI:16À28%). Overall arterial TE rate was 2% (95% CI: 1À4%): ICU, 5% (95%CI: 3À7%). Pooled mortality rate among patients with TE was 23% (95%CI:14À32%) and 13% (95% CI:6À22%) among patients without TE. The pooled odds of mortality were 74% higher among patients who developed TE compared to those who did not (OR, 1.74; 95%CI, 1.01À2.98; P = 0.04). Interpretation: TE rates of COVID-19 are high and associated with higher risk of death. Robust evidence from ongoing clinical trials is needed to determine the impact of thromboprophylaxis on TE and mortality risk of COVID-19. Funding: None.

show abstract

Section: Resultsmentioning

confidence: 99%

Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis

Malas¹,

Naazie²,

et al. 2020

View full text Add to dashboard Cite

show abstract

“…42 It is possible that many cases of VTE remain undiagnosed especially in non-hospitalized COVID-19 patients. 28…”

Section: Etiology and Pathogenesismentioning

confidence: 99%

Venous thromboembolism in the era of COVID-19

et al. 2020

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) does not only affect the respiratory system but appears to be a systemic disease. Venous thromboembolism is a common manifestation in hospitalized patients with COVID-19 with a reported incidence that is significantly higher compared to other acute viral infections. The pathophysiology mechanisms have not been fully explored and autopsy studies might enhance our understanding on this topic. Microthrombi formation occurs mainly in the pulmonary vasculature but can also occur in other organs. The high inflammatory burden related to COVID-19 seems to be associated with the coexisting coagulopathy. Concomitant manifestations of COVID-19, such as severe pneumonia, which has similar clinical presentation with pulmonary embolism (PE), and barriers related to strict isolation protocols are the two main reasons why PE diagnosis might be more challenging in patients with COVID-19. Medical societies have published guidance reports suggesting the administration of prophylactic anticoagulant therapy in hospitalized patients with COVID-19, but several questions regarding the optimal acute and long-term treatment of these patients remain unanswered.

show abstract

“…Cette incidence est corrélée à la gravité de la maladie. Alors que les estimations de la fréquence des patients atteints en ville est moins connue (proportion tout à fait inhabituelle d’un tiers des morts subites extrahospitalières liées aux ETEV [1] ), celles concernant les patients hospitalisés révèlent les chiffres suivants : entre 6 et 14 % [2] , [3] chez les patients présentant un COVID-19 nécessitant une hospitalisation et entre 17 % et 50 % [2] , [3] , [4] , [5] , [6] , [7] chez les patients les plus graves hospitalisés en réanimation. Ces discordances peuvent être expliquées par des populations de risque variable (suspects ou non d’embolie pulmonaire), voire des designs différents (dépistage systématique chez des patients consécutifs versus populations sélectionnées).…”

Section: Quel Risque De Thrombose Veineuse Au Cours Du Covid-19 ?unclassified

Thrombose artérielle et veineuse au cours du COVID-19

Zuily

Dufrost

Wahl

2020

Archives des Maladies du Coeur et des Vaisseaux - Pratique

View full text Add to dashboard Cite

Excess out‐of‐hospital deaths during the COVID‐19 outbreak: evidence of pulmonary embolism as a main determinant

Cited by 32 publications

References 8 publications

Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis

Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis

Venous thromboembolism in the era of COVID-19

Thrombose artérielle et veineuse au cours du COVID-19

Contact Info

Product

Resources

About